{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:35:57Z","timestamp":1794339357412,"version":"4.9.0"},"reference-count":36,"publisher":"Japanese Society of Internal Medicine","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,11,15]]},"DOI":"10.2169\/internalmedicine.9261-21","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T22:11:34Z","timestamp":1648851094000},"page":"3383-3390","source":"Crossref","is-referenced-by-count":14,"title":["Successful Control of Hypercalcemia with Sorafenib, Evocalcet, and Denosumab Combination Therapy for Recurrent Parathyroid Carcinoma"],"prefix":"10.2169","volume":"61","author":[{"given":"Hirofumi","family":"Makino","sequence":"first","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Notsu","sequence":"additional","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsuko","family":"Asayama","sequence":"additional","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazuki","family":"Otani","sequence":"additional","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Morita","sequence":"additional","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Japan"},{"name":"Research Institute for Metabolic Bone Diseases, Eikokai Ono Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Nakao","sequence":"additional","affiliation":[{"name":"Cancer Genome Medical Center, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Unnan City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Araki","sequence":"additional","affiliation":[{"name":"Organ Pathology Unit, Department of Pathology, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Uchino","sequence":"additional","affiliation":[{"name":"Noguchi Thyroid Clinic and Hospital Foundation, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keizo","family":"Kanasaki","sequence":"additional","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 86: 538-544, 1999.","DOI":"10.1002\/(SICI)1097-0142(19990801)86:3<538::AID-CNCR25>3.3.CO;2-B"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Shane E. Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab 86: 485-493, 2001.","DOI":"10.1210\/jcem.86.2.7207"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol 13: 11-23, 2012.","DOI":"10.1007\/s11864-011-0171-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sandelin K, Auer G, Bondeson L, Grimelius L, Farnebo LO. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg 16: 724-731, 1992.","DOI":"10.1007\/BF02067369"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Rozhinskaya L, Pigarova E, Sabanova E, et al. Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases. Endocrinol Diabetes Metab Case Rep 2017: 16-0113, 2017.","DOI":"10.1530\/EDM-16-0113"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Alharbi N, Asa SL, Szybowska M, Kim RH, Ezzat S. Intrathyroidal parathyroid carcinoma: an atypical thyroid lesion. Front Endocrinol (Lausanne) 9: 641, 2018.","DOI":"10.3389\/fendo.2018.00641"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Akirov A, Asa SL, Larouche V, et al. The clinicopathological spectrum of parathyroid carcinoma. Front Endocrinol (Lausanne) 10: 731, 2019.","DOI":"10.3389\/fendo.2019.00731"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kutahyalioglu M, Nguyen HT, Kwatampora L, et al. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol 145: 1977-1986, 2019.","DOI":"10.1007\/s00432-019-02945-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hara H, Igarashi A, Yano Y, et al. Ultrasonographic features of parathyroid carcinoma. Endocr J 48: 213-217, 2001.","DOI":"10.1507\/endocrj.48.213"},{"key":"10","first-page":"649","volume":"101","author":"KE Levin","year":"1987","unstructured":"10. Levin KE, Galante M, Clark OH. Parathyroid carcinoma versus parathyroid adenoma in patients with profound hypercalcemia. Surgery 101: 649-660, 1987.","journal-title":"Surgery","ISSN":"https:\/\/id.crossref.org\/issn\/0039-6060","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Woodhouse R, Li M, Hughes J, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One 15: e0237802, 2020.","DOI":"10.1371\/journal.pone.0237802"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Carpten JD, Robbins CM, Villablanca A, et al. <i>HRPT2<\/i>, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32: 676-680, 2002.","DOI":"10.1038\/ng1048"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Juhlin C, Larsson C, Yakoleva T, et al. Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr Relat Cancer 13: 509-523, 2006.","DOI":"10.1677\/erc.1.01058"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sulaiman L, Haglund F, Hashemi J, et al. Genome-wide and locus specific alterations in <i>CDC73\/HRPT2<\/i>-mutated parathyroid tumors. PLoS One 7: e46325, 2012.","DOI":"10.1371\/journal.pone.0046325"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Cetani F, Marcocci C, Torregrossa L, Pardi E. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocr Relat Cancer 26: R441-R464, 2019.","DOI":"10.1530\/ERC-19-0135"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Newey PJ, Bowl MR, Cranston T, Thakker RV. Cell division cycle protein 73 homolog (<i>CDC73<\/i>) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat 31: 295-307, 2010.","DOI":"10.1002\/humu.21188"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Erovic BM, Harris L, Jamali M, et al. Biomarkers of parathyroid carcinoma. Endocr Pathol 23: 221-231, 2012.","DOI":"10.1007\/s12022-012-9222-y"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Calapkulu M, Gul OO, Cander S, et al. Control of refractory hypercalcemia with denosumab in a case of metastatic parathyroid carcinoma. J Coll Physicians Surg Pak 30: 757-759, 2020.","DOI":"10.29271\/jcpsp.2020.07.757"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kebebew E. Parathyroid carcinoma. Curr Treat Options Oncol 2: 347-354, 2001.","DOI":"10.1007\/s11864-001-0028-2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore) 71: 197-205, 1992.","DOI":"10.1097\/00005792-199207000-00002"},{"key":"21","doi-asserted-by":"crossref","first-page":"e92061","DOI":"10.1172\/jci.insight.92061","volume":"2","author":"C Pandya","year":"2017","unstructured":"21. Pandya C, Uzilov AV, Bellizzi J, et al. Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight 2: e92061, 2017.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kasaian K, Wiseman SM, Thiessen N, et al. Complete genomic landscape of a recurring sporadic parathyroid carcinoma. J Pathol 230: 249-260, 2013.","DOI":"10.1002\/path.4203"},{"key":"23","unstructured":"23. Jackson CE, Norum RA, Boyd SB, et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 108: 1006-1012; discussion 1012-1013, 1990."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140, 2008.","DOI":"10.1158\/1535-7163.MCT-08-0013"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Krupinova J, Mokrysheva N, Pigarova E, Gorbunova V, Voronkova I, Rozhinskaya L. Multikinase inhibitors for the treatment of progressive, metastatic parathyroid cancer. Proceedings of the 21st European Congress of Endocrinology; 2019 May 18-21; Lyon, France: Endocrine Abstracts. Forthcoming.","DOI":"10.1530\/endoabs.63.GP227"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Hsieh JJ, Chen D, Wang PI, et al. Genomic Biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma. Eur Urol 71: 405-414, 2017.","DOI":"10.1016\/j.eururo.2017.01.013"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat 53: 100715, 2020.","DOI":"10.1016\/j.drup.2020.100715"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Fendrich V, Waldmann J, Feldmann G, et al. Unique expression pattern of the EMT markers Snail, Twist and E-cadherin in benign and malignant parathyroid neoplasia. Eur J Endocrinol 160: 695-703, 2009.","DOI":"10.1530\/EJE-08-0662"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 92: 3803-3808, 2007.","DOI":"10.1210\/jc.2007-0585"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Takeuchi Y, Nishida Y, Kondo Y, Imanishi Y, Fukumoto S. Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study. J Bone Miner Metab 38: 687-694, 2020.","DOI":"10.1007\/s00774-020-01097-y"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Haven CJ, van Puijenbroek M, Karperien M, Fleuren GJ, Morreau H. Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J Pathol 202: 86-94, 2004.","DOI":"10.1002\/path.1489"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Minezaki M, Takashi Y, Ochi K, et al. Reduction in parathyroid adenomas by cinacalcet therapy in patients with primary hyperparathyroidism. J Bone Miner Metab 39: 583-588, 2021.","DOI":"10.1007\/s00774-020-01190-2"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Ichii M, Ishimura E, Okuno S, et al. Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 115: c195-c202, 2010.","DOI":"10.1159\/000313035"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Yano S, Sugimoto T, Tsukamoto T, et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int 58: 1980-1986, 2000.","DOI":"10.1111\/j.1523-1755.2000.00370.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20: 757-766, 2003.","DOI":"10.1023\/B:CLIN.0000006873.65590.68"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sahi C, Knox JJ, Hinder V, et al. The effects of sorafenib and sunitinib on bone turnover markers in patients with bone metastases from renal cell carcinoma. J Clin Oncol 27 (Suppl 15): e16145, 2009.","DOI":"10.1200\/jco.2009.27.15_suppl.e16145"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/22\/61_9261-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:30:43Z","timestamp":1715315443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/22\/61_9261-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":36,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9261-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"article-number":"9261-21"}}